Literature DB >> 11943420

MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt.

Francesco Salerno1, Manuela Merli, Massimo Cazzaniga, Valentina Valeriano, Plinio Rossi, Andrea Lovaria, Daniele Meregaglia, Antonio Nicolini, Lorenzo Lubatti, Oliviero Riggio.   

Abstract

BACKGROUND/AIMS: Patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) are at risk of early death due to end-stage liver failure. The aim of this study was to compare model of end-stage liver disease (MELD) and Child-Pugh scores as predictors of survival after TIPS.
METHODS: We studied 140 cirrhotic patients treated with elective TIPS. Concordance (c)-statistic was used to assess the ability of MELD or Child-Pugh scores to predict 3-month survival. The prediction of overall survivals was estimated by comparing actuarial curves of subgroups of patients stratified according to either Child-Pugh scores or MELD risk scores.
RESULTS: During a median follow-up of 23.7 months, 55 patients died, 14 underwent liver transplantation and seven were lost to follow-up. For 3-month survival, the discrimination power of MELD score was superior to Child-Pugh score (0.84 vs. 0.70, z=2.07; P=0.038). Unlike Pugh score, MELD score identified two subgroups of Child C patients with different overall survivals (P=0.027). The comparison between observed and predicted survivals showed that MELD score overrates death risk.
CONCLUSIONS: MELD score is superior to Child-Pugh score as predictor of short-term outcome after TIPS. Its accuracy, however, decreases for long-term predictions.

Entities:  

Mesh:

Year:  2002        PMID: 11943420     DOI: 10.1016/s0168-8278(01)00309-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  58 in total

1.  TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Whalen C Clark; Donald P Thometz; Thomas J Black; Bruce R Zwiebel; Bruce T Kudryk; L Shane Grundy; Larry C Carey
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

2.  Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.

Authors:  Renato Ripamonti; Hector Ferral; Marc Alonzo; Nilesh H Patel
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

3.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

4.  Paradigms in the management of hepatic hydrothorax: past, present, and future.

Authors:  Sachin Kumar; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2012-09-25       Impact factor: 6.047

Review 5.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

6.  General aspects of the treatment of alcoholic hepatitis.

Authors:  Michael J Babineaux; Bhupinderjit S Anand
Journal:  World J Hepatol       Date:  2011-05-27

Review 7.  Percutaneous Portosystemic Shunts: TIPS and Beyond.

Authors:  Leigh C Casadaban; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 8.  Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up.

Authors:  Alexander Copelan; Baljendra Kapoor; Mark Sands
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

9.  Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis.

Authors:  Ying Peng; Xingshun Qi; Junna Dai; Hongyu Li; Xiaozhong Guo
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 10.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.